Global Genomics Group
G3 Therapeutics (G3T) is a pre-clinical stage biotechnology company focused on drug discovery and development, anchored in human genetic target validation. They leverage a unique platform that combines deep, panomic biological big data with machine learning (ML) and artificial intelligence (AI) to identify and validate potential drug targets for various diseases. The company has sequenced every gene in the human genome across thousands of individuals and measured hundreds of thousands of biomarkers, enabling them to connect drug targets with specific disease states. G3T aims to create revelationary therapies by translating deep human biology into novel treatments, with a business model centered on partnering with pharmaceutical, biopharmaceutical, and biotechnology companies for specific assets or broader discovery programs. They also offer services for target validation and diagnostic identification. Their pipeline includes multiple novel drug candidates currently in in-vitro studies. Traction is indicated by cumulatively enrolling nearly 10,000 patients across its clinical programs.
Global Genomics Group
G3 Therapeutics (G3T) is a pre-clinical stage biotechnology company focused on drug discovery and development, anchored in human genetic target validation. They leverage a unique platform that combines deep, panomic biological big data with machine learning (ML) and artificial intelligence (AI) to identify and validate potential drug targets for various diseases. The company has sequenced every gene in the human genome across thousands of individuals and measured hundreds of thousands of biomarkers, enabling them to connect drug targets with specific disease states. G3T aims to create revelationary therapies by translating deep human biology into novel treatments, with a business model centered on partnering with pharmaceutical, biopharmaceutical, and biotechnology companies for specific assets or broader discovery programs. They also offer services for target validation and diagnostic identification. Their pipeline includes multiple novel drug candidates currently in in-vitro studies. Traction is indicated by cumulatively enrolling nearly 10,000 patients across its clinical programs.